Summit Therapeutics Reports First Quarter Results for the Three Months Ended 30 April 2015

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Summit Therapeutics Reports First Quarter Results for the Three Months Ended 30 April 2015

Summit Therapeutics (SMMT) SMT C1100 Fully Enrolled in Trial Phase Ib; Needham & Company Reiterates Buy

June 12, 2015 7:30 AM EDT

Needham & Company reiterates a Buy rating and $22.00 price target on Summit Therapeutics plc (NASDAQ: SMMT) as SMT C1100 pharmacokinetics and muscle biomarkers trial is now fully enrolled and dosing patients. topline data is expected in 3Q15.

Analyst Chad Messer commented, "Summit... More

Summit Therapeutics (SMMT) Reports Q1 Loss of 6p/Share

June 11, 2015 7:07 AM EDT

Summit Therapeutics (NASDAQ: SMMT) reported Q1 EPS of (GBP0.06), versus (GBP0.08) reported last year.

Mr Glyn Edwards, Chief Executive Officer of Summit commented: "During the first quarter, we substantially expanded our shareholder base with a successful NASDAQ listing, which has provided significant support for the on-going patient clinical trials of our lead product... More